Three things to know:
1. Two studies demonstrated NervGen’s NVG-291 technology to support nerve remyelination in spinal cord injury and MS animal models, making it a significant opportunity to become a therapeutic for MS.
2. MS involves the immune system attacking the protective myelin sheath that covers nerve fibers, leading to communication issues between the brain and body, which can result in the deterioration of the nerves and permanent damage including the inability to walk.
3. Recent findings from a National MS Society Study published in the journal Neurology found that almost 1 million adults were living with MS in the U.S. and 2.3 million people worldwide.
“As we advance our lead drug candidate, NVG-291, towards a Phase 1 clinical trial in Q1 2020 for spinal cord injury, we are leveraging the potential for our drug to also promote nerve remyelination as a therapy for MS,” said Bill Radvak, NervGen’s executive chairman.
More articles on biologics:
SEC ends investigation into Misonix over Chinese business partner
Zimmer Biomet replaces retiring CFO
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
